Top Markets
#1 ADO Protocol ADO Protocol +193.36%
#2 Islamic Coin Islamic Coin +155.22%
#3 GoPlus Security GoPlus Security +45.23%
#4 Siren Siren +42.82%
#5 GAIB AID GAIB AID +24.80%
#6 Casper Network Casper Network +19.86%
#7 Starpower Starpower +15.89%
#8 Verus Coin Verus Coin +13.74%
#9 o1.exchange o1.exchange +12.92%
#10 Pons Pons +12.30%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
NeoImmuneTech, Inc. NeoImmuneTech, Inc.

NeoImmuneTech, Inc.

950220
Rank in Stocks #33504
As a clinical-stage biotechnology firm with a strong focus on T cells,... As a clinical-stage biotechnology firm with a strong focus on T cells, NeoImmuneTech, Inc. is dedicated to creating and marketing innovative immunotherapies. The company's lead product, NT-I7, is a long-acting human IL-7 currently in clinical development for its potential to treat a range of oncologic and infectious conditions. Founded in 2014, NeoImmuneTech is based in Rockville, Maryland.
Share Price
$1.12
Last synced: 2026-08-14
Market Cap
$7.52M
Change (1 day)
4.51%
Change (1 year)
-94.79%
Country
US
Trade NeoImmuneTech, Inc. (950220)

Category

Healthcare
P/E ratio for NeoImmuneTech, Inc. (950220)
P/E ratio as of 2026 TTM: 0
According to NeoImmuneTech, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for NeoImmuneTech, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.